Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Di-tert-butyl 9H-purin-6-yliMidodicarbonate is a chemical compound with the molecular formula C18H26N8O6. It is a derivative of purine, a nitrogenous base commonly found in DNA and RNA. di-tert-butyl 9H-purin-6-yliMidodicarbonate is characterized by its di-tert-butyl groups, which provide steric hindrance, making it a valuable reagent in organic chemistry for the selective protection of specific functional groups during chemical reactions. Its potential pharmacological properties, particularly as an antitumor agent, are of interest due to its ability to interfere with DNA replication and repair processes.

309947-86-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 309947-86-2 Structure
  • Basic information

    1. Product Name: di-tert-butyl 9H-purin-6-yliMidodicarbonate
    2. Synonyms: di-tert-butyl 9H-purin-6-yliMidodicarbonate;IMidodicarbonic acid, 2-(9H-purin-6-yl)-, 1,3-bis(1,1-diMethylethyl) ester;tert-Butyl N-tert-butoxycarbonyl-N-(7H-purin-6-yl)carbamate;tert-butyl N-[(2-methylpropan-2-yl)oxycarbonyl]-N-(7H-purin-6-yl)carbamate;tert-butyl N-[(tert-butoxy)carbonyl]-N-(9H-purin-6-yl)carbamate
    3. CAS NO:309947-86-2
    4. Molecular Formula: C15H21N5O4
    5. Molecular Weight: 335.35834
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 309947-86-2.mol
  • Chemical Properties

    1. Melting Point: 149-150 °C
    2. Boiling Point: 500.5±53.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.296±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: 9.59±0.10(Predicted)
    10. CAS DataBase Reference: di-tert-butyl 9H-purin-6-yliMidodicarbonate(CAS DataBase Reference)
    11. NIST Chemistry Reference: di-tert-butyl 9H-purin-6-yliMidodicarbonate(309947-86-2)
    12. EPA Substance Registry System: di-tert-butyl 9H-purin-6-yliMidodicarbonate(309947-86-2)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 309947-86-2(Hazardous Substances Data)

309947-86-2 Usage

Uses

Used in Organic Chemistry:
Di-tert-butyl 9H-purin-6-yliMidodicarbonate is used as a reagent for the protection of nucleobases during the synthesis of nucleosides. Its di-tert-butyl groups offer steric hindrance, which is crucial for selective protection of specific functional groups in chemical reactions.
Used in Pharmaceutical Research:
Di-tert-butyl 9H-purin-6-yliMidodicarbonate is studied for its potential as an antitumor agent. It is of interest in pharmaceutical research due to its ability to interfere with DNA replication and repair processes, which could be leveraged in the development of treatments for cancer.
Used in Drug Development:
In the field of drug development, di-tert-butyl 9H-purin-6-yliMidodicarbonate may be utilized as a lead compound for the creation of new pharmaceuticals targeting DNA-related processes, given its demonstrated potential to impact these mechanisms.

Check Digit Verification of cas no

The CAS Registry Mumber 309947-86-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,9,9,4 and 7 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 309947-86:
(8*3)+(7*0)+(6*9)+(5*9)+(4*4)+(3*7)+(2*8)+(1*6)=182
182 % 10 = 2
So 309947-86-2 is a valid CAS Registry Number.

309947-86-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-[(2-methylpropan-2-yl)oxycarbonyl]-N-(7H-purin-6-yl)carbamate

1.2 Other means of identification

Product number -
Other names N6-Diboc adenine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:309947-86-2 SDS

309947-86-2Relevant articles and documents

Synthesis of Rigid Rod, Trigonal, and Tetrahedral Nucleobase-Terminated Molecules

Jin, Xiao-Yang,Wu, Chuan-Shuo,Liu, An-Di,Liu, Li,Cheng, Liang

, p. 1643 - 1651 (2022/01/12)

An efficient fragment splicing method for the construction of multiple nucleobase-terminated monomers has been developed. Conformationally fixed rod, trigonal planar and tetrahedral thymine and adenine structures were generated in moderate to good yields,

Decatungstate-Mediated C(sp3)–H Heteroarylation via Radical-Polar Crossover in Batch and Flow

Capaldo, Luca,Frederick, Michael O.,García-Losada, Pablo,Laudadio, Gabriele,Mateos, Carlos,No?l, Timothy,Nu?o, Manuel,Nyuchev, Alexander V.,Rincón, Juan A.,Wan, Ting

supporting information, p. 17893 - 17897 (2021/07/14)

Photocatalytic hydrogen atom transfer is a very powerful strategy for the regioselective C(sp3)–H functionalization of organic molecules. Herein, we report on the unprecedented combination of decatungstate hydrogen atom transfer photocatalysis with the oxidative radical–polar crossover concept to access the direct net-oxidative C(sp3)–H heteroarylation. The present methodology demonstrates a high functional group tolerance (40 examples) and is scalable when using continuous-flow reactor technology. The developed protocol is also amenable to the late-stage functionalization of biologically relevant molecules such as stanozolol, (?)-ambroxide, podophyllotoxin, and dideoxyribose.

PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS

-

Paragraph 30-31, (2021/02/19)

The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

MLL1 INHIBITORS AND ANTI-CANCER AGENTS

-

Page/Page column 32, (2021/12/08)

The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical composit

MLL1 INHIBITORS AND ANTI-CANCER AGENTS

-

Page/Page column 30-31, (2021/04/01)

The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL).

Discovery of Nucleic Acid Binding Molecules from Combinatorial Biohybrid Nucleobase Peptide Libraries

Pomplun, Sebastian,Gates, Zachary P.,Zhang, Genwei,Quartararo, Anthony J.,Pentelute, Bradley L.

supporting information, p. 19642 - 19651 (2020/12/18)

Nature has three biopolymers: oligonucleotides, polypeptides, and oligosaccharides. Each biopolymer has independent functions, but when needed, they form mixed assemblies for higher-order purposes, as in the case of ribosomal protein synthesis. Rather tha

Base glycosylation method taking o-alkylenyl phenol ether as leaving group

-

Paragraph 0084-0085; 0087, (2019/07/04)

The invention discloses a method for building C-N glycosidic bond of nucleoside. The method is simple in operation, mild in condition and high in stereoselectivity and regioselectivityof reaction. Themethod includes: taking o-alkylenyl phenol ether as the

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

-

Page/Page column 125, (2015/09/22)

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leigh's disease.

Progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein- mediated multidrug efflux: Design, synthesis, characterization and biological evaluation

Zeinyeh, Wael,Mahiout, Zahia,Radix, Sylvie,Lomberget, Thierry,Dumoulin, Axel,Barret, Roland,Grenot, Catherine,Rocheblave, Luc,Walchshofer, Nadia,Matera, Eva-Laure,Dumontet, Charles

, p. 1177 - 1191,15 (2020/08/20)

Bivalent ligands were designed on the basis of the described close proximity of the ATP-site and the putative steroid-binding site of P-glycoprotein (ABCB1). The syntheses of 19 progesterone-adenine hybrids are described. Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone. The hybrid with a hexamethylene linker chain showed the best inhibitory potency. The efficiency of these progesterone-adenine hybrids depends on two main factors: (i) the nature of the linker and (ii) its attachment point on the steroid skeleton.

Regioselective alkylation of the exocyclic nitrogen of adenine and adenosine by the Mitsunobu reaction

Fletcher, Steven

scheme or table, p. 2948 - 2950 (2010/06/21)

A novel synthetic route to N6-substitution of adenine is presented, employing the Mitsunobu reaction as the key step. A range of primary and secondary alcohols all coupled in very good to excellent yields within 30 min at 45 °C, offering a milder alternative to the traditional nucleophilic aromatic substitution of 6-chloropurine. The utility of this protocol is further demonstrated by its application to the syntheses of N6,N9-di-substituted adenines, including the potent and selective A1 adenosine receptor agonist N6-cyclopentyladenosine.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 309947-86-2